516 related articles for article (PubMed ID: 19074459)
1. Phosphorylation does not prompt, nor prevent, the formation of alpha-synuclein toxic species in a rat model of Parkinson's disease.
Azeredo da Silveira S; Schneider BL; Cifuentes-Diaz C; Sage D; Abbas-Terki T; Iwatsubo T; Unser M; Aebischer P
Hum Mol Genet; 2009 Mar; 18(5):872-87. PubMed ID: 19074459
[TBL] [Abstract][Full Text] [Related]
2. G protein-coupled receptor kinase 5, overexpressed in the alpha-synuclein up-regulation model of Parkinson's disease, regulates bcl-2 expression.
Liu P; Wang X; Gao N; Zhu H; Dai X; Xu Y; Ma C; Huang L; Liu Y; Qin C
Brain Res; 2010 Jan; 1307():134-41. PubMed ID: 19852948
[TBL] [Abstract][Full Text] [Related]
3. Ser129D mutant alpha-synuclein induces earlier motor dysfunction while S129A results in distinctive pathology in a rat model of Parkinson's disease.
Febbraro F; Sahin G; Farran A; Soares S; Jensen PH; Kirik D; Romero-Ramos M
Neurobiol Dis; 2013 Aug; 56():47-58. PubMed ID: 23567651
[TBL] [Abstract][Full Text] [Related]
4. Accumulation of phosphorylated alpha-synuclein in dopaminergic neurons of transgenic mice that express human alpha-synuclein.
Wakamatsu M; Ishii A; Ukai Y; Sakagami J; Iwata S; Ono M; Matsumoto K; Nakamura A; Tada N; Kobayashi K; Iwatsubo T; Yoshimoto M
J Neurosci Res; 2007 Jun; 85(8):1819-25. PubMed ID: 17465029
[TBL] [Abstract][Full Text] [Related]
5. Generation of a alpha-synuclein-based rat model of Parkinson's disease.
Recchia A; Rota D; Debetto P; Peroni D; Guidolin D; Negro A; Skaper SD; Giusti P
Neurobiol Dis; 2008 Apr; 30(1):8-18. PubMed ID: 18313315
[TBL] [Abstract][Full Text] [Related]
6. Dopamine transporter-mediated cytotoxicity of 6-hydroxydopamine in vitro depends on expression of mutant alpha-synucleins related to Parkinson's disease.
Lehmensiek V; Tan EM; Liebau S; Lenk T; Zettlmeisl H; Schwarz J; Storch A
Neurochem Int; 2006 Apr; 48(5):329-40. PubMed ID: 16406146
[TBL] [Abstract][Full Text] [Related]
7. Ventral tegmental area dopamine neurons are resistant to human mutant alpha-synuclein overexpression.
Maingay M; Romero-Ramos M; Carta M; Kirik D
Neurobiol Dis; 2006 Sep; 23(3):522-32. PubMed ID: 16806952
[TBL] [Abstract][Full Text] [Related]
8. Controlling the mass action of alpha-synuclein in Parkinson's disease.
Kim C; Lee SJ
J Neurochem; 2008 Oct; 107(2):303-16. PubMed ID: 18691382
[TBL] [Abstract][Full Text] [Related]
9. Phosphorylation of α-synuclein upregulates tyrosine hydroxylase activity in MN9D cells.
Wu B; Liu Q; Duan C; Li Y; Yu S; Chan P; Uéda K; Yang H
Acta Histochem; 2011 Jan; 113(1):32-5. PubMed ID: 19683335
[TBL] [Abstract][Full Text] [Related]
10. Nuclear and neuritic distribution of serine-129 phosphorylated alpha-synuclein in transgenic mice.
Schell H; Hasegawa T; Neumann M; Kahle PJ
Neuroscience; 2009 Jun; 160(4):796-804. PubMed ID: 19272424
[TBL] [Abstract][Full Text] [Related]
11. alpha-Synuclein and its disease-related mutants interact differentially with the microtubule protein tau and associate with the actin cytoskeleton.
Esposito A; Dohm CP; Kermer P; Bähr M; Wouters FS
Neurobiol Dis; 2007 Jun; 26(3):521-31. PubMed ID: 17408955
[TBL] [Abstract][Full Text] [Related]
12. A molecular pathway of neurodegeneration linking alpha-synuclein to ApoE and Abeta peptides.
Gallardo G; Schlüter OM; Südhof TC
Nat Neurosci; 2008 Mar; 11(3):301-8. PubMed ID: 18297066
[TBL] [Abstract][Full Text] [Related]
13. Alpha-synuclein aggregation in neurodegenerative diseases and its inhibition as a potential therapeutic strategy.
Paleologou KE; Irvine GB; El-Agnaf OM
Biochem Soc Trans; 2005 Nov; 33(Pt 5):1106-10. PubMed ID: 16246056
[TBL] [Abstract][Full Text] [Related]
14. Silencing of human alpha-synuclein in vitro and in rat brain using lentiviral-mediated RNAi.
Sapru MK; Yates JW; Hogan S; Jiang L; Halter J; Bohn MC
Exp Neurol; 2006 Apr; 198(2):382-90. PubMed ID: 16455076
[TBL] [Abstract][Full Text] [Related]
15. Viral vectors, animal models and new therapies for Parkinson's disease.
Schneider B; Zufferey R; Aebischer P
Parkinsonism Relat Disord; 2008; 14 Suppl 2():S169-71. PubMed ID: 18585946
[TBL] [Abstract][Full Text] [Related]
16. [Modelling synucleinopathies in genetically modified animals--successes and failures].
Ninkina NN; Ustiugov AA; Bukhman VL
Mol Biol (Mosk); 2008; 42(5):840-55. PubMed ID: 18988533
[TBL] [Abstract][Full Text] [Related]
17. Parkinson's disease genetic mutations increase cell susceptibility to stress: mutant alpha-synuclein enhances H2O2- and Sin-1-induced cell death.
Jiang H; Wu YC; Nakamura M; Liang Y; Tanaka Y; Holmes S; Dawson VL; Dawson TM; Ross CA; Smith WW
Neurobiol Aging; 2007 Nov; 28(11):1709-17. PubMed ID: 16978743
[TBL] [Abstract][Full Text] [Related]
18. The role of ubiquitin linkages on alpha-synuclein induced-toxicity in a Drosophila model of Parkinson's disease.
Lee FK; Wong AK; Lee YW; Wan OW; Chan HY; Chung KK
J Neurochem; 2009 Jul; 110(1):208-19. PubMed ID: 19457126
[TBL] [Abstract][Full Text] [Related]
19. Alpha-synuclein dysfunction in Lewy body diseases.
Tofaris GK; Spillantini MG
Mov Disord; 2005 Aug; 20 Suppl 12():S37-44. PubMed ID: 16092089
[TBL] [Abstract][Full Text] [Related]
20. The role of Ser129 phosphorylation of α-synuclein in neurodegeneration of Parkinson's disease: a review of in vivo models.
Sato H; Kato T; Arawaka S
Rev Neurosci; 2013; 24(2):115-23. PubMed ID: 23314528
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
